MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Agenus EV/EBITDA Ratio 2011-2026 | AGEN
Annual EV/EBITDA Ratio Agenus
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -8.96 | -5.1 | -8.07 | -2.91 | -4.58 | -3.78 | -3.75 | -8.02 | -3.09 | -23 | -4.64 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.91 | -23 | -6.89 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-0.994 | $ 5.15 | 15.21 % | $ 12.4 B |  Australia |
 |
Allakos
ALLK
|
-1.56 | - | - | $ 28.6 M |  USA |
 |
AlloVir
ALVR
|
-3.61 | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
595 | - | - | $ 866 M |  China |
 |
Applied Molecular Transport
AMTI
|
-1.19 | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B | USA |
 |
Applied Therapeutics
APLT
|
-0.476 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-1.56 | - | -39.0 % | $ 4.57 M | USA |
 |
Genfit SA
GNFT
|
4.22 K | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | France |
 |
Advaxis
ADXS
|
-82.4 | - | -9.65 % | $ 45.9 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | USA |
 |
Akouos
AKUS
|
-1.13 | - | 0.23 % | $ 488 M | USA |
 |
Midatech Pharma plc
MTP
|
0.796 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aligos Therapeutics
ALGS
|
-2.41 | $ 6.51 | -2.54 % | $ 64.4 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
17.3 | $ 22.92 | 0.17 % | $ 1.07 B | USA |
 |
Avenue Therapeutics
ATXI
|
0.871 | - | -52.27 % | $ 4.45 M | USA |
 |
BioNTech SE
BNTX
|
4.1 | $ 105.19 | 2.21 % | $ 27.2 B | Germany |
 |
Aravive
ARAV
|
-0.158 | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - |  Russia |
 |
Can-Fite BioPharma Ltd.
CANF
|
-43.1 | $ 3.0 | -1.32 % | $ 4.94 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
4.4 | - | 5.93 % | $ 314 M |  Canada |
 |
AstraZeneca PLC
AZN
|
76.5 | - | - | $ 96.9 B | Britain |
 |
AgeX Therapeutics
AGE
|
-1.85 | - | -10.17 % | $ 12.2 K | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-5.59 | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-2.4 | $ 1.43 | 1.78 % | $ 368 M | USA |
 |
BioDelivery Sciences International
BDSI
|
8 | - | -4.8 % | $ 255 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
0.785 | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.546 | - | - | $ 26.5 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-208 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aquestive Therapeutics
AQST
|
-7.26 | $ 4.24 | -1.85 % | $ 453 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-4.86 | $ 24.47 | -0.24 % | $ 3.11 B | USA |
 |
AIkido Pharma
AIKI
|
-45.5 | - | 1.93 % | $ 17.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.38 | $ 1.58 | -1.25 % | $ 420 M | Britain |
 |
Aptose Biosciences
APTO
|
388 | - | -45.71 % | $ 1.2 M | Canada |
 |
BioXcel Therapeutics
BTAI
|
-2.43 | $ 1.2 | 4.35 % | $ 14.6 M | USA |
 |
AVROBIO
AVRO
|
0.957 | - | 1083.1 % | $ 745 M | USA |
 |
Cabaletta Bio
CABA
|
0.778 | $ 3.31 | -3.92 % | $ 333 M | USA |
 |
bluebird bio
BLUE
|
-0.805 | - | - | $ 546 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
0.832 | $ 6.73 | -0.88 % | $ 192 M | USA |
 |
Akero Therapeutics
AKRO
|
-4.64 | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | Germany |
 |
CymaBay Therapeutics
CBAY
|
-1.63 K | - | - | $ 3.45 B | USA |
 |
Cidara Therapeutics
CDTX
|
-1.47 | - | - | $ 1.41 B | USA |
 |
ChromaDex Corporation
CDXC
|
-5.05 | - | -0.88 % | $ 598 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
0.298 | - | 3.16 % | $ 1.9 M | USA |
 |
ContraFect Corporation
CFRX
|
-2.36 | - | -5.16 % | $ 5.39 M | USA |